Abstract:Benign prostatic hyperplasia and prostate cancer are tumoral pathologies characterized by the overexpression of inflammatory processes. The exploration of tumor microenvironment and understanding the sequential events that take place in the stromal area of the prostate could help for an early management of these pathologies. This way, it is feasible the hypothesis that normalizing the stromal environment would help to suppress or even to reverse tumor fenotype. A number of immunological and genetic factors, endocrine dysfunctions, metabolic disorders, infectious foci, nutritional deficiencies, and chemical irritants could be involved in prostate tumor development by maintaining inflammation, affecting local microcirculation, and promoting oxidative stress. Inflammatory processes activate hyperproliferative programs that ensure fibromuscular growth of the prostate and a number of extracellular changes. Acute and chronic inflammations cause accumulation of immunocompetent cells in affected prostate tissue (T cells, macrophages, mastocytes, dendritic cells, neutrophils, eosinophils, monocytes). Prostate epithelial and stromal cells, peri-prostatic fat cells, prostatic microvascular endothelial cells, and inflammatory cells produce cytokines, generating a local inflammatory environment. Interleukin-6 (IL-6) proved to be involved in the prostate tumor pathogenesis. IL-6 ability to induce pro- and anti-inflammatory responses by three mechanisms of signal transduction (classical signaling, transsignaling, cluster signaling), to interact with a diversity of target cells, to induce endocrine effects in an autocrine/paracrine manner, and the identification of an IL-6 endogenous antagonist that blocks the transmission of IL-6 mediated intracellular signals could justify current theories on the protective effects of this cytokine or by alleviating inflammatory reactions or by exacerbating tissue damage. This analysis presents recent data about the role of the inflammatory process as a determining factor in the development of benign and malign prostate tumors. The presented findings could bring improvements in the field of physiopathology, diagnosis, and treatment in patients with prostate tumors. Modulation of the expression and activity of interleukin-6 could be a mean of preventing or improving these pathologies.

IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells

Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.

PPARγ2 Functions As a Tumor Suppressor in a Translational Mouse Model of Human Prostate Cancer

Effect of Interleukin-6 on growth and STAT3 signal transduction pathway in human pancreatic cancer cell line

IL-6 Signaling Link between Inflammatory Tumor Microenvironment and Prostatic Tumorigenesis

The role of peroxisome proliferator-activated receptor gamma in prostate cancer

Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer

Peroxisome proliferator-activated receptor gamma regulates interleukin-6 induced lipoprotein(a) gene expression in human HepG2 cells

[The Effect of Ligand of Peroxisome Proliferators-Activated Receptor Gamma 15D-Pgj2 on the Proliferation and Activation of Hepatic Stellate Cells].

Induction of proliferative and mutagenic activity by benzo(a)pyrene in PC-3 cells via JAK2/STAT3 pathway

Dynamic Soluble IL-6R/Soluble gp130 Ratio as a Potential Indicator for the Prostate Malignancy Phenotype—A Multicenter Case–Control Study

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

IL-6 is associated to IGF-1Ec upregulation and Ec peptide secretion, from prostate tumors

Effects of IL-6 and AG490 on Regulation of Stat3 Signaling Pathway and Invasion of Human Pancreatic Cancer Cells in Vitro

Selective activation of PPARgamma in breast, colon, and lung cancer cell lines

Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells

Effects and mechanism of 15-deoxy-prostaglandin J 2 on proliferation and apoptosis of human HepG 2 cells

PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.

Effect of Interleukin-6 on the Growth of Human Lung Cancer Cell Line.

PPARγ Ligands Inhibit Cholangiocarcinoma Cell Growth Through P53-Dependent GADD45 and P21waf1/cip1 Pathway

15-Deoxy-delta12,14-prostaglandin J2 regulates leukemia inhibitory factor signaling through JAK-STAT pathway in mouse embryonic stem cells